Role of PCA3 test in clinical decision making for prostate cancer diagnosis

Table 3 Univariable associations with post PCA3 biopsy result

	Post PCA3 biopsy result		OR (95%CI)	P value
	Normal benign (n = 88)	CAP (n = 44)
PCA3 [Mean (SD)]	34.8 (34.6)	73.3 (84.6)	1.02 (1.01, 1.02)	0.003
PCA3 > 15.0	57 (64.8%)	40 (90.9%)	5.44 (1.78, 16.62)	0.003
PCA3 > 20.0	52 (59.1%)	37 (84.1%)	3.66 (1.47, 9.12)	0.005
PCA3 > 25.0	46 (52.3%)	34 (77.3%)	3.10 (1.37, 7.05)	0.007
PCA3 > 35.0	35 (39.8%)	29 (65.9%)	2.93 (1.38, 6.23)	0.005
PSA [Mean (SD)]	9.3 (5.1)	11.4 (10.1)	1.04 (0.99, 1.09)	0.126
PSA > 4.0	86 (97.7%)	42 (95.5%)	0.49 (0.07, 3.59)	0.481
PSA > 7.5	48 (54.6%)	22 (50.0%)	0.83 (0.40, 1.72)	0.622
Inflammation	28 (31.8%)	16 (36.4%)	1.22 (0.57, 2.62)	0.602
Family history	4 (4.6%)	7 (15.9%)	3.97 (1.10, 14.40)	0.036
Last biopsy result-HGPIN/ASAP	24 (27.3%)	25 (56.8%)	3.51 (1.64, 7.49)	0.001
Abnormal DRE	13 (14.8%)	14 (31.8%)	2.69 (1.13, 6.40)	0.025

HGPIN/ASAP: High grade prostatic intraepithelial neoplasia/atypical small acinar proliferation; CAP: Carcinoma of prostate; DRE: Digital rectal examination; SD: Standard deviation.